FDA: Abuse/Misuse of OTC Nasal Decongestant Can Lead to Major Health Complications
Since January 1, 2000, there have been 460 documented cases of propylhexedrine abuse or misuse reported to US poison control centers.
Cough and Cold
Gefapixant Under Review for Refractory Chronic Cough
The NDA submission is based on data from the double-blind, placebo-controlled phase 3 studies, COUGH-1 and COUGH-2.
Mucinex Children’s FreeFrom OTC Cough/Cold Products Now Available
Mucinex® Children’s FreeFrom™, a new line of over-the-counter cough and cold products free from artificial flavors, colors, and dyes, has been made available by Reckitt Benckiser.
OTC Medicines Containing “Clean” Inactive Ingredients Launched
Genexa has launched 4 over-the-counter (OTC) medicines that contain no artificial ingredients.
Statistically Significant Reduction in Cough Frequency Observed in Gefapixant Trials
The double-blind, placebo-controlled studies, COUGH-1 and COUGH-2, included 730 and 1314 adult patients with refractory or unexplained chronic cough for at least 1 year, respectively.
Betadine OTC Product Line Expands With Antiseptic Sore Throat Gargle
Betadine Antiseptic Sore Throat Gargle is indicated for adults and children 12 years of age and older.
Pharmacologic Ingredients in OTC Sinonasal Products Often Redundant
The same 8 nonanalgesic active ingredients were found in hundreds of brand name over-the-counter sinonasal products.
OTC Cough/Cold Meds Recalled Due to Incorrect Dosing Cups
GlaxoSmithKline (GSK) Consumer Healthcare announced the voluntary recall of 2 lots of Children’s Robitussin® Honey Cough and Chest Congestion DM and 1 lot of Children’s Dimetapp® Cold and Cough due to the inclusion of incorrect dosing cups.
Gefapixant Looks Promising for Refractory, Unexplained Chronic Cough
Merck announced topline data from 2 ongoing pivotal phase 3 trials (COUGH-1 and COUGH-2) for gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough.
Recommendations Decreased for Cough, Cold Medicine in US
Recommendations for opioid-containing, nonopioid cough and cold medicines reduced in pediatric population
